Which CAR T cell therapy will receive the next FDA approval in 2024? | Categorical | | | 7 months ago | |
Will Bristol Myers Squibb report increased sales of Breyanzi in Q3 2024? | Binary | | | 7 months ago | |
Will FDA approve another expansion for Breyanzi by end of 2024? | Binary | | | 7 months ago | |
Will Bristol Myers Squibb's stock price outperform, underperform, or match its competitors in Q4 2024? | Categorical | | | 7 months ago | |
Bristol Myers' CAR-T market share by 2026 | Categorical | | | 8 months ago | |
Revenue from BMS-Cellares CAR-T deal by 2026 | Categorical | | | 8 months ago | |
New CAR-T therapy indication approval by 2025? | Binary | | | 8 months ago | |
Will Prime Medicine's stock price reach $10 per share by December 31, 2024? | Binary | | | 3 months ago | |
What will be Prime Medicine's stock price at the end of Q1 2025? | Categorical | | | 3 months ago | |
Cobenfy (KarXT) approved by the EMA by June 30, 2025? | Binary | | | 3 months ago | |
Cobenfy (KarXT) commercially available in the U.S. by December 31, 2024? | Binary | | | 3 months ago | |
Will KarXT (Cobenfy) receive EMA approval by September 26, 2025? | Binary | | | 3 months ago | |
Which company will make the next major acquisition involving a CAR T cell therapy company in 2024? | Categorical | | | 7 months ago | |
Will Breyanzi become the leading CAR T cell therapy for mantle cell lymphoma by market share in 2024? | Binary | | | 7 months ago | |
Cellares gets expanded deal with Bristol Myers by 2026? | Binary | | | 8 months ago | |
Bristol Myers meets CAR-T production target by 2025? | Binary | | | 8 months ago | |
Will Bristol Myers Squibb's Cobenfy receive additional FDA approval by June 30, 2025? | Binary | | | 1 month ago | |
Which company will have better stock performance by end of 2024: AbbVie or Bristol Myers? | Categorical | | | 1 month ago | |
Will AbbVie's stock recover to pre-trial levels by March 31, 2025? | Binary | | | 1 month ago | |
Will Evotec announce a new drug candidate from the Bristol Myers Squibb collaboration by mid-2025? | Binary | | | 2 months ago | |
Will Bristol Myers Squibb make another investment in Evotec by the end of 2024? | Binary | | | 2 months ago | |
Will Bristol Myers Squibb and Evotec expand their collaboration beyond molecular glues by the end of 2025? | Binary | | | 2 months ago | |
How many new molecular glue-based projects will Evotec and Bristol Myers Squibb initiate by the end of 2025? | Categorical | | | 2 months ago | |
Will KarXT achieve over 10% market share in the schizophrenia drug market by the end of 2025? | Binary | | | 2 months ago | |
Will KarXT be recommended as a first-line treatment for schizophrenia by a major medical association by mid-2025? | Binary | | | 2 months ago | |
Will KarXT receive FDA approval for schizophrenia treatment by the end of 2024? | Binary | | | 2 months ago | |
Will Prime Medicine and Bristol Myers Squibb announce the initiation of a clinical trial for T-Cell Therapy by March 31, 2025? | Binary | | | 3 months ago | |
What will be the total milestone payments received by Prime Medicine from Bristol Myers Squibb by September 30, 2025? | Categorical | | | 3 months ago | |
Will Prime Medicine receive an additional development milestone payment from Bristol Myers Squibb by mid-2025? | Binary | | | 3 months ago | |
Will Prime Medicine achieve first development milestone with Bristol Myers Squibb by end of 2024? | Binary | | | 3 months ago | |
Will Prime Medicine's stock price increase by 20% or more by end of 2024? | Binary | | | 3 months ago | |
When will the first T-Cell therapy from Prime Medicine and Bristol Myers Squibb partnership enter clinical trials? | Categorical | | | 3 months ago | |
When will Prime Medicine's T-Cell therapy receive FDA approval? | Categorical | | | 3 months ago | |
Will Prime Medicine receive the first milestone payment from Bristol Myers Squibb by the end of 2024? | Binary | | | 3 months ago | |
Will Bristol Myers Squibb's stock price increase by more than 10% by the end of 2024? | Binary | | | 3 months ago | |
Will Cobenfy achieve $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
What will be Cobenfy's market share among schizophrenia treatments by the end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy receive a black box warning from the FDA by the end of 2025? | Binary | | | 3 months ago | |
Will Cobenfy achieve FDA fast-track designation for another indication by end of 2024? | Binary | | | 3 months ago | |
Will Cobenfy reach $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
How many new schizophrenia drugs will FDA approve by end of 2025? | Categorical | | | 3 months ago | |
What will Cobenfy's market share among schizophrenia treatments be by end of 2025? | Categorical | | | 3 months ago | |
Cobenfy (KarXT) generate over $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
Will KarXT (Cobenfy) become the leading schizophrenia treatment in the U.S. by prescription volume by September 26, 2025? | Binary | | | 3 months ago | |
Cellares' new pharma partnerships by 2025 | Categorical | | | 8 months ago | |
Which company will receive the next major FDA approval for schizophrenia treatment by end of 2025? | Categorical | | | 1 month ago | |
Will AbbVie announce new clinical trial results for Emraclidine by end of 2024? | Binary | | | 1 month ago | |
What will be AbbVie's next major strategic move by June 30, 2025? | Categorical | | | 1 month ago | |
When will the first major milestone payment from Bristol Myers Squibb to Evotec occur under the new collaboration? | Categorical | | | 2 months ago | |
By how much will Evotec's stock price increase due to the new collaboration by the end of 2024? | Categorical | | | 2 months ago | |
What will be the total revenue generated by KarXT in its first full year on the market in 2025? | Categorical | | | 2 months ago | |
How many countries will approve KarXT for schizophrenia treatment by the end of 2025? | Categorical | | | 2 months ago | |
What percentage of patients will experience significant improvement with KarXT by the end of 2025? | Categorical | | | 2 months ago | |
Will Prime Medicine receive the first milestone payment from Bristol Myers Squibb by September 30, 2025? | Binary | | | 3 months ago | |
How many Prime Edited Ex Vivo T-Cell Therapies will be in development by Prime Medicine and Bristol Myers Squibb by December 31, 2024? | Categorical | | | 3 months ago | |
When will Prime Medicine achieve its first commercialization milestone with Bristol Myers Squibb? | Categorical | | | 3 months ago | |
How will Prime Medicine stock perform by the end of 2024 following the Bristol Myers Squibb partnership announcement? | Categorical | | | 3 months ago | |
How many new therapies will Prime Medicine announce under the Bristol Myers Squibb collaboration by the end of 2024? | Categorical | | | 3 months ago | |
Will Prime Medicine achieve a significant clinical milestone in its collaboration with Bristol Myers Squibb by the end of 2025? | Binary | | | 3 months ago | |
How will Prime Medicine's market cap change by March 31, 2025 following the Bristol Myers Squibb partnership announcement? | Categorical | | | 3 months ago | |
Will Prime Medicine announce a new drug candidate under the Bristol Myers Squibb collaboration by June 30, 2025? | Binary | | | 3 months ago | |
How many new schizophrenia treatments will be approved by the FDA by the end of 2025? | Categorical | | | 3 months ago | |
What will be the peak annual sales of Cobenfy by the end of 2025? | Categorical | | | 3 months ago | |
What will be the peak annual sales of Cobenfy by end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy receive a negative safety review from FDA by end of 2024? | Binary | | | 3 months ago | |
Region with highest initial sales of Cobenfy (KarXT) in 2024? | Categorical | | | 3 months ago | |
Primary side effect reported for Cobenfy (KarXT) by end of 2024? | Categorical | | | 3 months ago | |
Major company announcing similar schizophrenia drug by end of 2025? | Categorical | | | 3 months ago | |
What sales milestone will KarXT (Cobenfy) achieve within the first year of launch? | Categorical | | | 3 months ago | |
Will KarXT (Cobenfy) achieve $500 million in sales within the first year of launch? | Binary | | | 3 months ago | |
How many new schizophrenia treatments will be approved by the FDA by September 26, 2025? | Categorical | | | 3 months ago | |
What percentage of U.S. schizophrenia patients will be using KarXT (Cobenfy) by September 26, 2025? | Categorical | | | 3 months ago | |